Cargando…

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy

Chemokine-like factor (CKLF)-like MARVEL transmembrane domain containing 6 (CMTM6) modulates degradation of a number of proteins, including programmed death ligand-1 (PD-L1) by protecting it from ubiquitin-mediated degradation. In this role, it could modulate the effectiveness of immunotherapy. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Morilla, Sandra, Zugazagoitia, Jon, Wong, Pok Fai, Kluger, Harriet M., Rimm, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781756/ https://www.ncbi.nlm.nih.gov/pubmed/33457084 http://dx.doi.org/10.1080/2162402X.2020.1864909

Ejemplares similares

Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma
por: Wong, Pok Fai, et al.
Publicado: (2019)

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2023)

Digital quantitative assessment of PD-L1 using digital spatial profiling
por: Gupta, Swati, et al.
Publicado: (2020)

Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
por: Gupta, Swati, et al.
Publicado: (2019)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
por: Smithy, James W., et al.
Publicado: (2017)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade
por: Vathiotis, Ioannis A., et al.
Publicado: (2022)

Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry
por: MacNeil, Tyler, et al.
Publicado: (2020)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
por: Zhao, Yanbin, et al.
Publicado: (2021)

CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well
por: Jiang, Xingyu, et al.
Publicado: (2022)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Drug targets and predictive biomarkers in the management of metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2012)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma
por: Gao, Hongli, et al.
Publicado: (2023)

Schwann-cell-derived CMTM6 restricts radial axonal growth
por: Elazar, Nimrod, et al.
Publicado: (2020)

MEK targeting in N-RAS mutated metastatic melanoma
por: Thumar, Jaykumar, et al.
Publicado: (2014)

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
por: Kluger, Harriet M, et al.
Publicado: (2007)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
por: Muranushi, Ryo, et al.
Publicado: (2021)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway
por: Wei, Li, et al.
Publicado: (2022)

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance
por: Schoenfeld, David A., et al.
Publicado: (2022)

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
por: Wang, Hanfeng, et al.
Publicado: (2022)

CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study
por: Huang, Xiaoting, et al.
Publicado: (2022)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma
por: Acs, Balazs, et al.
Publicado: (2019)

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer
por: MacNeil, Tyler, et al.
Publicado: (2021)

Benign lymph node microenvironment is associated with response to immunotherapy
por: Toki, Maria I, et al.
Publicado: (2020)

19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
por: Oria, Victor, et al.
Publicado: (2020)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Understanding heterogeneous tumor microenvironment in metastatic melanoma
por: Yan, Yiyi, et al.
Publicado: (2019)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9r9vbdbd73t8r4n3htstrht0tg